|
21 Sep 2018 |
Mylan and Biocon Announce Positive CHMP Opinion for Fulphila®, Biosimilar Pegfilgrastim
|
|
21 Sep 2018 |
Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease
|
|
21 Sep 2018 |
Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim
|
|
21 Sep 2018 |
Bayer receives positive CHMP opinion for its hemophilia A treatment BAY94-9027
|
|
21 Sep 2018 |
Novo Nordisk - Oral semaglutide demonstrates greater reductions in HbA1c and body weight and comparable number of adverse events vs dulaglutide in Japanese people with type 2 diabetes
|
|
21 Sep 2018 |
Cinfa Biotech receives positive CHMP opinion for Pelmeg(R) (pegfilgrastim), a proposed biosimilar to Neulasta(R)
|
|
19 Sep 2018 |
BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round
|
|
18 Sep 2018 |
Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
|
|
17 Sep 2018 |
Oramed Receives FDA Clearance for IND Application for Its Oral GLP-1 Analog Capsule
|
|
17 Sep 2018 |
Aeglea BioTherapeutics Announces Oral Presentation of Preclinical Data on New Pipeline Therapeutic for Cystinuria at 2018 American Society of Nephrology
|
|
15 Sep 2018 |
Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines
|
|
12 Sep 2018 |
Shire granted EU marketing authorization for Veyvondi® [vonicog alfa, recombinant von willebrand factor] for adults with von Willebrand disease
|
|
10 Sep 2018 |
Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab
|
|
10 Sep 2018 |
Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
|
|
06 Sep 2018 |
PvP Biologics Announces First-in-Human Clinical Trials for a Novel Therapeutic for Celiac Disease
|
|
06 Sep 2018 |
ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia
|
|
05 Sep 2018 |
Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke
|
|
04 Sep 2018 |
Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase in Patients with Arginase 1 Deficiency
|
|
30 Aug 2018 |
Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen
|
|
30 Aug 2018 |
European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes
|
|
28 Aug 2018 |
Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII
|
|
27 Aug 2018 |
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
|
|
26 Aug 2018 |
Ozempic® consistently reduced the risk of major cardiovascular events across type 2 diabetes populations at high CV risk regardless of prior CV events at baseline
|
|
23 Aug 2018 |
Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis
|
|
20 Aug 2018 |
Oral semaglutide provides superior HbA1c and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial
|
